Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

被引:5
|
作者
Zhao, Xin [1 ]
Li, Xinbao [2 ]
Lin, Yulin [2 ]
Ma, Ru [2 ]
Zhang, Ying [2 ]
Xu, Dazhao [2 ]
Li, Yan [1 ,2 ]
机构
[1] Peking Univ, Sch Clin Med 9, Dept Peritoneal Canc Surg, Beijing Shijitan Hosp, 10 Tieyi Rd,Yangfangdian St, Beijing 100038, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Dept Peritoneal Canc Surg, Beijing, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 03期
关键词
Bayesian network; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei; survival prognostic model; NEOPLASMS; OUTCOMES;
D O I
10.1002/cam4.5138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN). Methods 453 PMP patients were included from the database at our center. The dataset was divided into a training set to establish BN model and a testing set to perform internal validation at a ratio of 8:2. From the training set, univariate and multivariate analyses were performed to identify independent prognostic factors for BN model construction. The confusion matrix, receiver operating characteristic (ROC) curve and the area under curve (AUC) were used to evaluate the performance of the BN model. Results The univariate and multivariate analyses identified 7 independent prognostic factors: gender, previous operation history, histological grading, lymphatic metastasis, peritoneal cancer index, completeness of cytoreduction and splenectomy (all p < 0.05). Based on independent factors, the BN model of training set was established. After internal validation, the accuracy and AUC of the BN model were 70.3% and 73.5%, respectively. Conclusion The BN model provides a reasonable level of predictive performance for PMP patients undergoing CRS + HIPEC.
引用
收藏
页码:2637 / 2645
页数:9
相关论文
共 50 条
  • [41] Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy
    Su, Yan-Dong
    Zhao, Xin
    Ma, Ru
    Fu, Yu-Bin
    Yang, Zhi-Ran
    Wu, He-Liang
    Yu, Yang
    Yang, Rui
    Liang, Xin-li
    Du, Xue-Mei
    Chen, Yue
    Li, Yan
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2023, 40 (01)
  • [42] Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals
    Toshiyuki Kitai
    Masahiro Kawashima
    Kenya Yamanaka
    Kunio Ichijima
    Hideaki Fujii
    Susumu Mashima
    Yasuyuki Shimahara
    Surgery Today, 2011, 41 : 1219 - 1223
  • [43] DRUG SENSITIVITY TESTING IN CYTOREDUCTIVE SURGERY AND INTRAPERITONEAL CHEMOTHERAPY OF PSEUDOMYXOMA PERITONEI
    Bjersand, K.
    Mahteme, H.
    Sundstrom-Poromaa, I.
    Nygren, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 326 - 326
  • [44] Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia
    Galan, Alexandre
    Rousset, Pascal
    Mercier, Frederic
    Kepenekian, Vahan
    Valette, Pierre-Jean
    Glehen, Olivier
    Passot, Guillaume
    EJSO, 2018, 44 (11): : 1818 - 1823
  • [45] Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index
    Trilling, Bertrand
    Brind'Amour, Alexandre
    Hamad, Raphael
    Tremblay, Jean-Francois
    Dube, Pierre
    Mitchell, Andrew
    Sideris, Lucas
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [46] Prognostic value of circulating tumor markers in patients with Pseudomyxoma Peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Baratti, Dario
    Kusamura, Shigeki
    Martinetti, Antonia
    Seregni, Ettore
    Laterza, Barbara
    Oliva, Daniela G.
    Deraco, Marcello
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (08) : 2300 - 2308
  • [47] Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index
    Bertrand Trilling
    Alexandre Brind’Amour
    Raphael Hamad
    Jean-Francois Tremblay
    Pierre Dubé
    Andrew Mitchell
    Lucas Sidéris
    World Journal of Surgical Oncology, 19
  • [48] Pseudomyxoma peritonei - Short- and Long-term Results following cytoreductive Surgery and hyperthermic intraperitoneal Chemotherapy
    不详
    ZENTRALBLATT FUR CHIRURGIE, 2012, 137 (05): : 401 - 401
  • [49] Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Dario Baratti
    Shigeki Kusamura
    Antonia Martinetti
    Ettore Seregni
    Barbara Laterza
    Daniela G. Oliva
    Marcello Deraco
    Annals of Surgical Oncology, 2007, 14 : 2300 - 2308
  • [50] Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei
    Beane, Joal D.
    Wilson, Gregory C.
    Sutton, Jeffrey M.
    Shuai, Yongli
    Ramalingam, Lekshmi
    Jones, Heather L.
    Pingpank, James F., II
    Holtzman, Matthew P.
    Zureikat, Amer J.
    Ahrendt, Steven A.
    Zeh, Herbert J.
    Bartlett, David L.
    Choudry, Haroon A.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (05) : 1429 - 1436